In phase 2 , higher MRI activity ( cumulative number of new contrast-enhancing lesions [ 19 vs 3 , p = 0.062 ] and new T2 lesions [ 17 vs 3 , p = 0.066 ] ) and relapse activity ( 4 vs 1 , p = 0.389 ) were identified as nonsignificant trends in the treated vs sham arm over 6 months .